Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.
Saved in:
| Title: | Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy. |
|---|---|
| Authors: | Baldacci S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Brea EJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Facchinetti F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li Z; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts., Ngo K; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Malhotra S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Booker MA; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts., Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts., Chakravarti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hinchey C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Lococo F; Università Cattolica del Sacro Cuore, Rome, Italy.; Thoracic Surgery Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., D'Agnelli S; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Gnetti L; Pathology Unit, University Hospital of Parma, Parma, Italy., Campanini N; Department of Medicine and Surgery, University of Parma, Parma, Italy., Leonetti A; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Feng WW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tsai JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hartley AV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Locquet MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Fournel L; Thoracic Surgery Department, Hôpital Cochin AP-HP Centre, Université Paris Cité, Paris, France., Alifano M; Thoracic Surgery Department, Hôpital Cochin AP-HP Centre, Université Paris Cité, Paris, France., Mansuet-Lupo A; Department of Pathology, Hôpital Cochin AP-HP Centre, Université Paris Cité, Paris, France., Saldanha A; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Haller W; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Zasadil LM; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Zielinska M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bui K; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tuladhar B; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Ivanova EV; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Sequist LV; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Paweletz CP; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Smith EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Parker Institute for Cancer Immunotherapy, San Francisco, California., Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Parker Institute for Cancer Immunotherapy, San Francisco, California. |
| Source: | Cancer discovery [Cancer Discov] 2025 Nov 03; Vol. 15 (11), pp. 2235-2250. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
